Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.

Curtit E, Pivot X, Henriques J, Paget-Bailly S, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, Soulié P, Jouannaud C, Bourgeois H, Petit T, Tennevet I, Assouline D, Mathieu MC, Jacquin JP, Lavau-Denes S, Darut-Jouve A, Ferrero JM, Tarpin C, Lévy C, Delecroix V, Trillet-Lenoir V, Cojocarasu O, Meunier J, Pierga JY, Kerbrat P, Faure-Mercier C, Blanché H, Sahbatou M, Boland A, Bacq D, Besse C, Thomas G, Deleuze JF, Pauporté I, Romieu G, Cox DG.

Breast Cancer Res. 2017 Aug 22;19(1):98. doi: 10.1186/s13058-017-0888-4.

2.

Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancers.

Viala M, Alexandre M, Thezenas S, Lamy PJ, Maran-Gonzalez A, Gutowski M, Colombo PE, Romieu G, Jacot W, Guiu S.

Breast Cancer Res Treat. 2017 Oct;165(3):611-621. doi: 10.1007/s10549-017-4373-7. Epub 2017 Jul 6.

PMID:
28685212
3.

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort.

Pivot X, Romieu G, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, Soulié P, Jouannaud C, Bourgeois H, Petit T, Tennevet I, Assouline D, Mathieu MC, Jacquin JP, Lavau-Denes S, Darut-Jouve A, Ferrero JM, Tarpin C, Lévy C, Delecroix V, Trillet-Lenoir V, Cojocarasu O, Meunier J, Pierga JY, Agostini C, Kerbrat P, Faure-Mercier C, Blanché H, Sahbatou M, Boland A, Bacq D, Besse C, Calvo F, Renaud A, Deleuze JF, Pauporté I, Thomas G, Cox DG.

NPJ Breast Cancer. 2017 Feb 23;3:4. doi: 10.1038/s41523-017-0005-y. eCollection 2017.

4.

Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort.

Pivot X, Fumoleau P, Pierga JY, Delaloge S, Bonnefoi H, Bachelot T, Jouannaud C, Bourgeois H, Rios M, Soulié P, Jacquin JP, Lavau-Denes S, Kerbrat P, Cox D, Faure-Mercier C, Pauporte I, Gligorov J, Curtit E, Henriques J, Paget-Bailly S, Romieu G.

Eur J Cancer. 2017 Aug;81:151-160. doi: 10.1016/j.ejca.2017.05.020. Epub 2017 Jun 16.

PMID:
28624696
5.

New advances in DPYD genotype and risk of severe toxicity under capecitabine.

Etienne-Grimaldi MC, Boyer JC, Beroud C, Mbatchi L, van Kuilenburg A, Bobin-Dubigeon C, Thomas F, Chatelut E, Merlin JL, Pinguet F, Ferrand C, Meijer J, Evrard A, Llorca L, Romieu G, Follana P, Bachelot T, Chaigneau L, Pivot X, Dieras V, Largillier R, Mousseau M, Goncalves A, Roché H, Bonneterre J, Servent V, Dohollou N, Château Y, Chamorey E, Desvignes JP, Salgado D, Ferrero JM, Milano G.

PLoS One. 2017 May 8;12(5):e0175998. doi: 10.1371/journal.pone.0175998. eCollection 2017.

6.

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.

Pierga JY, Bidard FC, Autret A, Petit T, Andre F, Dalenc F, Levy C, Ferrero JM, Romieu G, Bonneterre J, Lerebours F, Bachelot T, Kerbrat P, Campone M, Eymard JC, Mouret-Reynier MA, Gligorov J, Hardy-Bessard AC, Lortholary A, Soulie P, Boher JM, Proudhon C, Charafe-Jaufret E, Lemonnier J, Bertucci F, Viens P.

Ann Oncol. 2017 Jan 1;28(1):103-109. doi: 10.1093/annonc/mdw535.

PMID:
28177480
7.

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.

Lefebvre C, Bachelot T, Filleron T, Pedrero M, Campone M, Soria JC, Massard C, Lévy C, Arnedos M, Lacroix-Triki M, Garrabey J, Boursin Y, Deloger M, Fu Y, Commo F, Scott V, Lacroix L, Dieci MV, Kamal M, Diéras V, Gonçalves A, Ferrerro JM, Romieu G, Vanlemmens L, Mouret Reynier MA, Théry JC, Le Du F, Guiu S, Dalenc F, Clapisson G, Bonnefoi H, Jimenez M, Le Tourneau C, André F.

PLoS Med. 2016 Dec 27;13(12):e1002201. doi: 10.1371/journal.pmed.1002201. eCollection 2016 Dec.

8.

GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients.

Cox DG, Curtit E, Romieu G, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, Soulié P, Jouannaud C, Bourgeois H, Petit T, Tennevet I, Assouline D, Mathieu MC, Jacquin JP, Lavau-Denes S, Darut-Jouve A, Ferrero JM, Tarpin C, Lévy C, Delecroix V, Trillet-Lenoir V, Cojocarasu O, Meunier J, Pierga JY, Faure-Mercier C, Blanché H, Sahbatou M, Boland A, Bacq D, Besse C, Deleuze JF, Pauporté I, Thomas G, Pivot X.

Oncotarget. 2016 Nov 22;7(47):77358-77364. doi: 10.18632/oncotarget.12669.

9.

Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?

Darlix A, Lamy PJ, Lopez-Crapez E, Braccini AL, Firmin N, Romieu G, Thézenas S, Jacot W.

Int J Cancer. 2016 Nov 15;139(10):2299-311. doi: 10.1002/ijc.30290. Epub 2016 Aug 6.

10.

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers.

Ferrari A, Vincent-Salomon A, Pivot X, Sertier AS, Thomas E, Tonon L, Boyault S, Mulugeta E, Treilleux I, MacGrogan G, Arnould L, Kielbassa J, Le Texier V, Blanché H, Deleuze JF, Jacquemier J, Mathieu MC, Penault-Llorca F, Bibeau F, Mariani O, Mannina C, Pierga JY, Trédan O, Bachelot T, Bonnefoi H, Romieu G, Fumoleau P, Delaloge S, Rios M, Ferrero JM, Tarpin C, Bouteille C, Calvo F, Gut IG, Gut M, Martin S, Nik-Zainal S, Stratton MR, Pauporté I, Saintigny P, Birnbaum D, Viari A, Thomas G.

Nat Commun. 2016 Jul 13;7:12222. doi: 10.1038/ncomms12222.

11.

Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients.

Darlix A, Lamy PJ, Lopez-Crapez E, Braccini AL, Firmin N, Romieu G, Thezenas S, Jacot W.

BMC Cancer. 2016 Jul 7;16:428. doi: 10.1186/s12885-016-2448-1.

12.

Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.

Jacot W, Pons E, Frenel JS, Guiu S, Levy C, Heudel PE, Bachelot T, D'Hondt V, Darlix A, Firmin N, Romieu G, Thezenas S, Dalenc F.

Breast Cancer Res Treat. 2016 Jun;157(2):307-318. doi: 10.1007/s10549-016-3828-6. Epub 2016 May 11.

PMID:
27167986
13.

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GK, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, van't Veer L, Tutt A, Knappskog S, Tan BK, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.

Nature. 2016 Jun 2;534(7605):47-54. doi: 10.1038/nature17676. Epub 2016 May 2.

14.

Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.

Bertucci F, Fekih M, Autret A, Petit T, Dalenc F, Levy C, Romieu G, Bonneterre J, Ferrero JM, Kerbrat P, Soulie P, Mouret-Reynier MA, Bachelot T, Lerebours F, Eymard JC, Deblock M, Lortholary A, Hardy-Bessard AC, Barthelemy P, Bonnefoi H, Charafe-Jauffret E, Bidard FC, Viens P, Lemonnier J, Pierga JY.

Lancet Oncol. 2016 May;17(5):600-11. doi: 10.1016/S1470-2045(16)00011-5. Epub 2016 Mar 28.

PMID:
27032301
15.

Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study.

Jacot W, Firmin N, Roca L, Topart D, Gallet S, Durigova A, Mirr S, Abach L, Pouderoux S, D'Hondt V, Bleuse JP, Lamy PJ, Romieu G.

Ann Oncol. 2016 Jul;27(7):1235-41. doi: 10.1093/annonc/mdw145. Epub 2016 Mar 30.

PMID:
27029707
16.

A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer.

Curigliano G, Romieu G, Campone M, Dorval T, Duck L, Canon JL, Roemer-Becuwe C, Roselli M, Neciosup S, Burny W, Callegaro A, de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF.

Breast Cancer Res Treat. 2016 Apr;156(2):301-10. doi: 10.1007/s10549-016-3750-y. Epub 2016 Mar 14.

PMID:
26975189
17.

Concurrent or sequential letrozole with adjuvant breast radiotherapy: final results of the CO-HO-RT phase II randomized trial.

Bourgier C, Kerns S, Gourgou S, Lemanski C, Gutowski M, Fenoglietto P, Romieu G, Crompton N, Lacombe J, Pèlegrin A, Ozsahin M, Rosenstein B, Azria D.

Ann Oncol. 2016 Mar;27(3):474-80. doi: 10.1093/annonc/mdv602. Epub 2015 Dec 17.

18.

High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers.

Jacot W, Mollevi C, Fina F, Lopez-Crapez E, Martin PM, Colombo PE, Bibeau F, Romieu G, Lamy PJ.

BMC Cancer. 2015 Dec 18;15:986. doi: 10.1186/s12885-015-1977-3.

19.

[uPA/PAI-1, Oncotype DX™, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management].

Luporsi E, Bellocq JP, Barrière J, Bonastre J, Chetritt J, Le Corroller AG, de Cremoux P, Fina F, Gauchez AS, Lamy PJ, Martin PM, Mazouni C, Peyrat JP, Romieu G, Verdoni L, Mazeau-Woynar V, Kassab-Chahmi D; Institut National du Cancer.

Bull Cancer. 2015 Sep;102(9):719-29. doi: 10.1016/j.bulcan.2015.05.003. Epub 2015 Jul 30. French. No abstract available.

20.

Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer.

Diéras V, Campone M, Yardley DA, Romieu G, Valero V, Isakoff SJ, Koeppen H, Wilson TR, Xiao Y, Shames DS, Mocci S, Chen M, Schmid P.

Ann Oncol. 2015 Sep;26(9):1904-10. doi: 10.1093/annonc/mdv263. Epub 2015 Jul 22.

PMID:
26202594
21.

Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study.

Pivot X, Suter T, Nabholtz JM, Pierga JY, Espie M, Lortholary A, Khayat D, Pauporte I, Romieu G, Kramar A, Fumoleau P.

Eur J Cancer. 2015 Sep;51(13):1660-6. doi: 10.1016/j.ejca.2015.05.028. Epub 2015 Jul 7.

PMID:
26163096
22.

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.

Diéras V, Wildiers H, Jassem J, Dirix LY, Guastalla JP, Bono P, Hurvitz SA, Gonçalves A, Romieu G, Limentani SA, Jerusalem G, Lakshmaiah KC, Roché H, Sánchez-Rovira P, Pienkowski T, Seguí Palmer MÁ, Li A, Sun YN, Pickett CA, Slamon DJ.

Breast. 2015 Jun;24(3):182-90. doi: 10.1016/j.breast.2014.11.003. Epub 2015 Mar 5.

PMID:
25747197
23.

Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.

Krop IE, Suter TM, Dang CT, Dirix L, Romieu G, Zamagni C, Citron ML, Campone M, Xu N, Smitt M, Gianni L.

J Clin Oncol. 2015 Apr 1;33(10):1136-42. doi: 10.1200/JCO.2014.58.7782. Epub 2015 Feb 23.

24.

[uPA/PAI-1, Oncotype DX™, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management].

Bellocq JP, Luporsi E, Barrière J, Bonastre J, Chetritt J, Le Corroller AG, de Crémoux P, Fina F, Gauchez AS, Kassab-Chahmi D, Lamy PJ, Martin PM, Mazouni C, Peyrat JP, Romieu G, Verdoni L, Mazeau-Woynar V.

Ann Pathol. 2014 Oct;34(5):349-51. doi: 10.1016/j.annpat.2014.04.010. Epub 2014 Aug 22. French.

PMID:
25439987
25.

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.

von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J.

Lancet Oncol. 2014 Oct;15(11):1269-78. doi: 10.1016/S1470-2045(14)70439-5. Epub 2014 Sep 28.

PMID:
25273342
26.

Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions?

Guiu S, Wolfer A, Jacot W, Fumoleau P, Romieu G, Bonnetain F, Fiche M.

Crit Rev Oncol Hematol. 2014 Dec;92(3):235-57. doi: 10.1016/j.critrevonc.2014.07.003. Epub 2014 Jul 30. Review.

PMID:
25129506
27.

[Breast cancer: radiotherapy and estrogen signaling].

Bourgier C, Lemanski C, Romieu G, Ozsahin M, Azria D.

Bull Cancer. 2014 Jul-Aug;101(7-8):714-7. doi: 10.1684/bdc.2014.1954. Review. French.

PMID:
25091654
28.

Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial.

Kramar A, Bachelot T, Madrange N, Pierga JY, Kerbrat P, Espié M, Fumoleau P, Pauporté I, Khayat D, Romieu G, Pivot X.

Ann Oncol. 2014 Aug;25(8):1563-70. doi: 10.1093/annonc/mdu177. Epub 2014 May 14.

PMID:
24827132
29.

Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer.

Saadoun H, Lamy PJ, Thezenas S, Pouderoux S, Bibeau F, Montels F, Romieu G, Colombo PE, Gutowski M, Jacot W.

Future Oncol. 2014 Feb;10(2):195-209. doi: 10.2217/fon.13.177.

PMID:
24490606
30.

HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort.

Rouanet P, Roger P, Rousseau E, Thibault S, Romieu G, Mathieu A, Cretin J, Barneon G, Granier M, Maran-Gonzalez A, Daures JP, Boissiere F, Bibeau F.

Cancer Med. 2014 Feb;3(1):134-42. doi: 10.1002/cam4.167. Epub 2014 Jan 10.

31.

BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.

Jacot W, Thezenas S, Senal R, Viglianti C, Laberenne AC, Lopez-Crapez E, Bibeau F, Bleuse JP, Romieu G, Lamy PJ.

BMC Cancer. 2013 Nov 5;13:523. doi: 10.1186/1471-2407-13-523.

32.

Cancer-related fatigue in breast cancer patients after surgery: a multicomponent model using partial least squares-path modeling.

Bortolon C, Krikorian A, Carayol M, Brouillet D, Romieu G, Ninot G.

Psychooncology. 2014 Apr;23(4):444-51. doi: 10.1002/pon.3438. Epub 2013 Oct 22.

PMID:
24150929
33.

[Vitamin D and breast cancer: physiopathology, biological and clinical implications].

Firmin N, Lamy PJ, Romieu G, Jacot W.

Bull Cancer. 2014 Mar;101(3):266-82. doi: 10.1684/bdc.2013.1826. Review. French.

PMID:
24103818
34.

Adapted physical activity and diet (APAD) during adjuvant breast cancer therapy: design and implementation of a prospective randomized controlled trial.

Carayol M, Romieu G, Bleuse JP, Senesse P, Gourgou-Bourgade S, Sari C, Jacot W, Sancho-Garnier H, Janiszewski C, Launay S, Cousson-Gélie F, Ninot G.

Contemp Clin Trials. 2013 Nov;36(2):531-43. doi: 10.1016/j.cct.2013.09.016. Epub 2013 Oct 4.

PMID:
24096188
35.

Risk-adapted, dose escalation study of weekly docetaxel in the first-line treatment of elderly patients with advanced cancer.

Culine S, Terret C, Cupissol D, Romieu G, Fabbro M, Pouessel D, Droz JP, Gourgou S.

J Geriatr Oncol. 2013 Apr;4(2):122-7. doi: 10.1016/j.jgo.2012.11.002. Epub 2012 Dec 14.

PMID:
24071537
36.

Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.

Pierga JY, Bidard FC, Cropet C, Tresca P, Dalenc F, Romieu G, Campone M, Mahier Aït-Oukhatar C, Le Rhun E, Gonçalves A, Leheurteur M, Dômont J, Gutierrez M, Curé H, Ferrero JM, Labbe-Devilliers C, Bachelot T.

Ann Oncol. 2013 Dec;24(12):2999-3004. doi: 10.1093/annonc/mdt348. Epub 2013 Sep 6.

PMID:
24013510
37.

[Physical activity and cancer survival].

Romieu I, Touillaud M, Ferrari P, Bignon YJ, Antoun S, Berthouze-Aranda S, Bachmann P, Duclos M, Ninot G, Romieu G, Sénesse P, Behrendt J, Balosso J, Pavic M, Kerbrat P, Serin D, Trédan O, Fervers B.

Bull Cancer. 2012 Oct;99(10):979-94. doi: 10.1684/bdc.2012.1648. French.

38.

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.

Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, Bubuteishvili-Pacaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R.

Lancet Oncol. 2013 Sep;14(10):933-42. doi: 10.1016/S1470-2045(13)70335-8. Epub 2013 Aug 7.

PMID:
23932548
39.

Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.

Crown JP, Diéras V, Staroslawska E, Yardley DA, Bachelot T, Davidson N, Wildiers H, Fasching PA, Capitain O, Ramos M, Greil R, Cognetti F, Fountzilas G, Blasinska-Morawiec M, Liedtke C, Kreienberg R, Miller WH Jr, Tassell V, Huang X, Paolini J, Kern KA, Romieu G.

J Clin Oncol. 2013 Aug 10;31(23):2870-8. doi: 10.1200/JCO.2012.43.3391. Epub 2013 Jul 15.

PMID:
23857972
40.

Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.

Braccini AL, Azria D, Thezenas S, Romieu G, Ferrero JM, Jacot W.

Breast. 2013 Oct;22(5):993-8. doi: 10.1016/j.breast.2013.05.011. Epub 2013 Jul 3.

PMID:
23831232
41.

Anemia and iron biomarkers in patients with early breast cancer. Diagnostic value of hepcidin and soluble transferrin receptor quantification.

Durigova A, Lamy PJ, Thezenas S, Pouderoux S, Montels F, Romieu G, Gutowski M, Jacot W.

Clin Chem Lab Med. 2013 Sep;51(9):1833-41. doi: 10.1515/cclm-2013-0031.

PMID:
23787470
42.

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A; PHARE trial investigators.

Lancet Oncol. 2013 Jul;14(8):741-8. doi: 10.1016/S1470-2045(13)70225-0. Epub 2013 Jun 11.

PMID:
23764181
43.

Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06.

Villanueva C, Romieu G, Salvat J, Chaigneau L, Merrouche Y, N'guyen T, Vuillemin AT, Demarchi M, Dobi E, Pivot X.

Target Oncol. 2013 Jun;8(2):137-43. doi: 10.1007/s11523-013-0279-4. Epub 2013 Apr 23.

PMID:
23609057
44.

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Moore N, Prot S, Pallaud C, Semiglazov V.

J Clin Oncol. 2013 May 10;31(14):1719-25. doi: 10.1200/JCO.2012.44.7912. Epub 2013 Apr 8.

PMID:
23569311
45.

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.

Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortés J, Delmar PR, Scherer SJ.

Br J Cancer. 2013 Mar 19;108(5):1052-60. doi: 10.1038/bjc.2013.69. Epub 2013 Feb 19.

46.

Comparative performances of prognostic indexes for breast cancer patients presenting with brain metastases.

Braccini AL, Azria D, Thezenas S, Romieu G, Ferreri JM, Jacot W.

BMC Cancer. 2013 Feb 8;13:70. doi: 10.1186/1471-2407-13-70.

47.

Re: clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review.

Lamy PJ, Martin PM, Romieu G, Jacot W.

J Natl Cancer Inst. 2013 Jan 16;105(2):149. doi: 10.1093/jnci/djs492. Epub 2012 Dec 14. No abstract available.

PMID:
23243205
48.

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.

Bachelot T, Romieu G, Campone M, Diéras V, Cropet C, Dalenc F, Jimenez M, Le Rhun E, Pierga JY, Gonçalves A, Leheurteur M, Domont J, Gutierrez M, Curé H, Ferrero JM, Labbe-Devilliers C.

Lancet Oncol. 2013 Jan;14(1):64-71. doi: 10.1016/S1470-2045(12)70432-1. Epub 2012 Nov 2.

PMID:
23122784
49.

Perceived sources of stress in fifth year dental students--a comparative study.

Manolova MS, Stefanova VP, Panayotov IV, Romieu G, Belcheva AB, Markova KB, Levallois B.

Folia Med (Plovdiv). 2012 Apr-Jun;54(2):52-9.

PMID:
23101286
50.

Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.

Coudert B, Asselain B, Campone M, Spielmann M, Machiels JP, Pénault-Llorca F, Serin D, Lévy C, Romieu G, Canon JL, Orfeuvre H, Piot G, Petit T, Jerusalem G, Audhuy B, Veyret C, Beauduin M, Eymard JC, Martin AL, Roché H; UNICANCER Breast Group.

Oncologist. 2012;17(7):900-9. doi: 10.1634/theoncologist.2011-0442. Epub 2012 May 18.

Supplemental Content

Loading ...
Support Center